Mostrando entradas con la etiqueta Farmacéuticos. Mostrar todas las entradas
Mostrando entradas con la etiqueta Farmacéuticos. Mostrar todas las entradas

miércoles, 9 de mayo de 2012

Bioeconomy Blueprint Embraces Public-Private Efforts, Avoids Grand Challenges

ORIGINAL: GenEngNews
Alex Philippidis

Priorities also included improving translational sciences, regulatory processes, and training programs.

The President’s National Bioeconomy Blueprint outlines how Washington intends to apply biological innovations toward national challenges that include health, food, energy, and the environment. [© Vacclav - Fotolia.com]
President Barack Obama’s administration rolled out its National Bioeconomy Blueprint last week, on April 26. It details measures by which Washington intends to apply biological innovations toward national challenges that include health, food, energy, and the environment.

At the top of the Blueprint’s five priorities is 
  1. supporting “R&D investments that will provide the foundation for the future U.S. bioeconomy.” Also on the list: 
  2. increasing the focus on translational and regulatory sciences, 
  3. reforming regulations, 
  4. updating training programs, and 
  5. identifying and supporting opportunities for public-private partnerships.

While those are all helpful components, the report should have also identified one or more “grand challenges”—a question asked in solicitation of public comment on the draft Blueprint last year. For example, developing tools to study the human immune system was the challenge suggested by Aprile L. Pilon, Ph.D., president and CEO of Clarassance. The firm is developing a recombinant human CC10 protein for prevention of neonatal bronchopulmonary dysplasia.

The Blueprint should have also outlined initiatives to assist small- and medium-sized businesses in maximizing their own contribution to the nation’s bioeconomy. In her comment to OSTP and an interview with GEN, for example, Dr. Pilon suggested increased funding for FDA’s Orphan Products Grant Program, which has stayed flat at $14 million for five years despite a growing number of funding applications. She also suggested more money for SBIR. The program’s recent reauthorization phases in 1% more funding over six years, but it also lets agencies use 3% toward administration, which takes away from grant money.

Bruce W. Stillman, Ph.D., president of Cold Spring Harbor Laboratory, offered grand-challenge suggestions that included launching a national Cancer Therapeutics Initiative, making a major commitment to fundamental neuroscience, investing in basic plant science to address energy and food needs, and continuing to invest in the training of scientists.


lunes, 7 de mayo de 2012

Synthetic Biological Life

ORIGINAL: HPlusMagazine
By: Laura E. Bratton, MD, Rodney Shackelford, DO, Ph.D.
May 3, 2012

The idea of producing artificial or synthetic life has long fascinated mankind and from ancient times many human and animal-imitating “automata” or self-operating machines have been created for entertainment, instructional, and sometimes religious purposes. The creation of actual synthetic biological life only became possible with the discovery of the structure of DNA, the genetic code, and the development of the basic tools of molecular biology, such as the ability to isolate, sequence, and join different DNA sequences. Especially important has been the recently developed ability to artificially synthesize relatively long DNA molecules with designed sequences. Although the creation of completely synthetic biological life was first accomplished in 2010, the field is already yielding significant information concerning the core gene groups or genetic “chassis” indispensible for life and how these gene products (proteins, RNAs, and lipids) function as an integrated unit. With the identification of these chassis, exogenous natural or synthetic gene sequences can be integrated into organisms designed for specific purposes and applications.

The first genetically engineered organism was created in 1973 when a naturally occurring DNA sequence was transferred into and expressed in a bacterium, conferring antibiotic resistance. The first organism to actually have a synthetic (or man-made “added”) biochemical pathway was created in 2003, when an E. coli was artificially created with a new genetic code and amino acid synthesizing enzymes. The engineered bacterium could synthesize and incorporate an amino acid (O-methyl-L-tyrosine) that does not normally occur in nature into proteins, increasing the number of amino acids used in virtually all life forms from twenty to twenty-one amino acids. Thus a new, human-designed functioning genetic chassis and genetic code was placed into a microorganism.

In 2010, after some fifteen years of intense research effort, the first entirely synthetic organism was created with a genome entirely synthesized “out of four bottles” i.e., chemically synthesized from the four DNA bases; thymine, cytosine, guanine, and adenine. The organism was partially based on M. mycoides, a genetically simple microorganism containing roughly 480 protein-encoding genes and a genome size of 1.08 million DNA base pairs – in comparison the human genome has roughly 20,500 genes over three billion DNA base pairs. The synthetic genome was chemically synthesized in 80-90 base units and slowly assembled into “DNA cassettes”, verified by sequencing, and assembled into a circular genome. To insure that no natural DNA contaminated the synthetic DNA “watermark” sequences were inserted into synthetic genome to differentiate it from the natural M. mycoides genome. Additionally, antibiotic resistance genes were added and a disease-inducing gene was removed from the synthetic genome. The resulting genome was place in an empty M. capricolum cell (i.e., without a nucleus) and the resulting synthetic life from was able to grow in culture indefinitely. Since 2010 this synthetic organism has been useful in identifying the “minimal genome” required for life – about 380 of the 480 protein-encoding genes. Additionally, comparison of the synthetic organism to similar naturally occurring organisms (Mycoplasmas), allowed the identification of gene groups involved in cellular processes such as 
  • information storage, 
  • metabolism, 
  • energy production and conversion, and 
  • cell membrane biogenesis. 
Identification of these gene sets is an important first step designing synthetic life that can perform specific functions.

Although a significant first step in the creation of synthetic biological life, this initial work met with extensive criticism. The researchers who made synthetic life were accused of “playing God” and possibly opening up a new technology that would allow the creation of “biological super weapons”. The later objection has some validity, as existing DNA synthesis and end-joining technology could allow the synthesis of fully infective polio or smallpox viruses. Other researchers pointed out that the new synthetic organism was a nearly one-to-one copy of a naturally occurring organism and for it to grow the synthetic genome had to be placed into a naturally occurring Mycoplasma that had its nucleus removed. Thus, other than the DNA being artificially synthesized, there was relatively little that was actually new about the organism. The creators of the new organism pointed out that this is a first step of many and “creating life from scratch” will come later.

Currently the immediate focus in synthetic biological life research is to use simple synthetic organisms to define the “minimal genome”, or the smallest set of genes required to support life and identify the components and functions of “biological gene-chassis” and find ways to modify these chassis. Specific applications include the creation of synthetic organisms that can: 
  1. efficiently produce pharmaceuticals and vaccines that are otherwise difficult and expensive to produce, 
  2. efficiently produce hydrocarbon biofuels (replacing oil, coal, etc.), and 
  3. be useful as plant feedstock in agriculture, lowering the need for increasingly expensive petroleum-based fertilizers. 
An example of such an application has been inserting the enzymes for artemisinic acid synthesis into baker’s yeast. Artemisinic acid is the chemical precursor anti-malarial drug artmisinin, a drug that is currently extracted from the sweet wormwood plant at high cost, reducing the drugs availability in poorer countries. Once the enzymatic pathway is in place and efficiently working, the drug could be produced cheaply in large amounts through a process resembling brewing beer. Several of these projects are being researched at Synthetic Genomics, a new biotechnology company specializing in the creation of synthetic life for specific applications.

Not surprisingly the creation of synthetic animal life is more complex and difficult than for simpler microorganisms. However, a round worm (C. elegans) was created that carried an extensively expanded genetic code and protein synthesis pathways, allowing the incorporation of multiple novel (or “unnatural”) amino acids into the animal’s proteins. These protein modifications would facilitate the study of protein localization and interactions within a living animal. Additionally, modified proteins could be designed for specific purposes, such as protein-based drugs with very long half-lives due to novel amino acids that inhibit normal cellular protein degradation.

Although difficult, our present molecular biology technology could allow the creation of more complex organisms, including fungi and even animals. The present challenges in creating synthetic life include the following:
  1. Create synthetic life “from scratch” without the need to largely copy existing life forms.
  2. Improve on our ability to design and integrate molecular pathways within synthetic life.
  3. Create a strategy or “algorithm” to for the efficient creation of synthetic life forms.
  4. Create policies and rules to prevent the creation of synthetic life forms that may be harmful, such as human pathogens (smallpox, virulent influenza viral types, etc.).
With time these goals could be achieved and the technology to accomplish these goals is largely in place.

In the more distant future synthetic biology could allow the extensive modification of existing genomes and even the creation of entirely new genomes and species. While this is the goal of many Transhumanists, one hopes that if and when such technology exists, the human race has the intelligence to apply such technology with wisdom.

Dr. Shackelford is an Assistant Professor of Clinical Pathology at Tulane Medical Center. He has a DO degree from Des Moines University of Osteopathic Medicine and a Ph.D. in molecular pathology from Duke University. His areas of research include DNA repair, molecular mechanisms of carcinogenesis, and cell division.

martes, 27 de marzo de 2012

Vaquitas Verdes (Little Green Cows)

ORIGINAL: IEET
Rachel Armstrong
Mar 27, 2012

The world is alight with algae fever.


Rachel Armstrong
In this age of deep ecological design aspirations, the range of speculative design projects based on algae technology is growing. Algae are imagined to provide a whole range of solutions, from
  • energy-producing architectural towers, to 
  • lights, 
  • burgers, 
  • skin care products, 
  • animal feed, 
  • drug factories and 
  • bioplastics. 
It finally appears that the world is turning green.

Literally.

Algae, simple photosynthetic plants that live in water, are among some of the oldest living organisms on earth.

Most species can only be seen with a microscope, but others can form dense mats of vegetation or large underwater forests. During the Archean period, between 3.9 and 3.5 billion years ago, blue-green algae* set the preconditions for modern life by changing the earth’s atmosphere, which was choked with poisonous gases, and turning it into an oxygen-rich environment. Their modern-day descendants can use a range of pigments to harvest specific wavelengths of light to form solid plant matter, or ‘biomass’, by using sunlight and carbon dioxide to produce fuel, water and oxygen.

Indeed, the ability of algae to fix carbon is such that they’ve become the technology of choice for carbon capture. We already know that they can make a large-scale impact. In fact, algae are so relentless, work so quickly and on such a scale that up until this moment in time they’ve been regarded in an extremely negative manner. Algae have been called by many names, most of them not at all complementary: Weeds, blight, bloom, deadly foam and literally, the scum of the earth. Despite their current reprieve as a possible solution to escalating carbon dioxide levels, there are still more products on the market designed to kill algae than ways to fruitfully use them.

An aquatic weed harvester in action at Lily Creek Lagoon, near Kununurra, Western Australia.

Designing with algae is an opportunity to creatively engage their technological potential in new ways, since they are not machines. Yet the modern synthetic biology industry, which takes a rational design and engineering approach to living systems, exists within an industrial framework. The model for the production process is the brewing industry. In a brewery, a living system, yeast, is introduced into a mechanical container where it performs the function of a tiny ‘machine’ that makes alcohol using natural raw ingredients. The container walls have no connection to the outside environment, so the yeast is ecologically ‘imprisoned’ and disconnected from nature. The process is also invisible to observers and the final product is assessed as a commodity rated purely in economic terms as a manufactured ‘product’. Its value is rated in comparison to the equivalent of a barrel of crude oil. It is not sold according to any other benefits of the process that relate to human experience.

This is a huge missed opportunity for synthetic biology to reach new customers and audiences. Biological systems do not just make useful products, but also offer significant environmental and people-centered benefits, which are neglected in the industrial approach. For example, algae bioreactors that use sunlight to fix carbon dioxide for the production of biofuels, which range from alcohol to oils, can also be designed as social experiences. IBA Hamburg promises the reality of a more integrated ecological design solution in its amazing new building facades for novel housing types.

So, rather than thinking of the algae as being ‘machines’ we could perhaps think of them as being ‘little green cows’. Imagine the algae bioreactors, which are simply aquariums, as a field in which oil-producing algae can graze on sunlight and carbon dioxide. These algae are circulated around the tank so that they have plenty to eat.

They are eventually moved into a milking shed in the form of a copper pipe, which gives the little green cows a tiny shock as they pass through, in a process called ‘cracking’. Absolutely no cows are hurt in the process, and by the end of a week a window-sized bioreactor will have produced a buttery layer of biofuel, which floats to the top of the collecting vessel like cream in a bottle of milk. The protein-rich waste can be recycled into soil fertilizer, or compressed into bricks for building with.

Many of the design issues raised in algae-based solutions prompt ecological thinking and approaches that are more frequently associated with creating ponds, gardens, farming and parks than making gadgets. So, thinking beyond the machine metaphor creates new ways of experiencing technology, and invites biology into our living spaces, which brings added benefits. Life is more robust, more adaptable and more surprising than machines can ever be. Uniquely, it also has the capacity to deal with ‘the unknown’ – something that simply cannot be modeled and programmed into mechanical systems. Consequently, when we view biology as being qualitatively different from machines, science and design are presented with new opportunities in ways of making and working with biology. Next nature explores this creative interface between biology, technology and humans, and inspires design solutions that are greater than the sum of their parts – which really is a lot more delightful than watching the inner workings of an oil refinery.


* Once considered true algae, blue-green algae, or cyanobacteria, are now classified as bacteria.



Image #1: via Celsias.


Image #2: Algae adrift in the interior of a bioreactor. Photo by author.